Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. | Wurschmidt et al. Radiation Oncology 2011 6 44 http content 6 1 44 RADIATION ONCOLOGY RESEARCH Open Access 18F fluoroethylcholine-PET CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET CT-positive lymph nodes 1 2 11 1 Florian Wurschmidt Cordula Petersen Andreas Wahl Jorg Dahle and Matthias Kretschmer Abstract Background At present there is no consensus on irradiation treatment volumes for intermediate to high-risk primary cancers or recurrent disease. Conventional imaging modalities such as CT MRI and transrectal ultrasound are considered suboptimal for treatment decisions. Choline-PET CT might be considered as the imaging modality in radiooncology to select and delineate clinical target volumes extending the prostate gland or prostate fossa. In conjunction with intensity modulated radiotherapy IMRT and imaged guided radiotherapy IGRT it might offer the opportunity of dose escalation to selected sites while avoiding unnecessary irradiation of healthy tissues. Methods Twenty-six patients with primary n 7 or recurrent n 19 prostate cancer received Choline-PET CT planned 3D conformal or intensity modulated radiotherapy. The median age of the patients was 65 yrs range 45 to 78 yrs . PET CT-scans with F18-fluoroethylcholine FEC were performed on a combined PET CT-scanner equipped for radiation therapy planning. The majority of patients had intermediate to high risk prostate cancer. All patients received 3D conformal or intensity modulated and imaged guided radiotherapy with megavoltage cone beam CT. The median dose to primary tumours was Gy and to FEC-positive recurrent lymph nodal sites 66 6 Gy. The median follow-up time was months. Results The mean SUVmax in primary cancer was 5 97 in the prostate gland and 3 2 in pelvic lymph nodes. Patients with recurrent cancer had a mean SUVmax of 4 38. Two patients had negative PET CT scans. At 28 months the overall survival rate is 94 . .
